IBI188 + decitabine

**IBI188 + decitabine** is an experimental combination therapy under investigation for the treatment of acute myeloid leukemia (AML). **IBI188** is a monoclonal antibody targeting CD47, functioning as a "don't eat me" signal inhibitor to promote macrophage-mediated phagocytosis of cancer cells. **Decitabine** is a DNA methyltransferase inhibitor (a hypomethylating agent) that induces DNA hypomethylation and cell differentiation/apoptosis. The combination aims to leverage the immunotherapeutic effects of IBI188 with the epigenetic modulatory and cytotoxic properties of decitabine. This combination is in clinical trials primarily for AML, particularly in patients ineligible for intensive chemotherapy.